Two back-to-back reports have jointly demonstrated that erasing α-SMA-expressing myofibroblasts in two different genetically engineered mouse models (GEMM) of PDAC resulted in a more aggressive tumor and did not improve gemcitabine’s efficacy, owing to suppressed immune surveillance and increased tumor vascularization, respectively [13, 14]. This evidence concerns the gene ACTA1 and neoplasm.